(lp0
S'Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference GlobeNewswire  - Mar 17, 2017 CAMBRIDGE, Mass., March 17, 2017  -- Sarepta Therapeutics, Inc. , a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of&nbsp;...'
p1
aS"2 Reasons Behind Sarepta Therapeutics Inc.'s 6.9% February Jump Motley Fool - Mar 3, 2017 Sarepta also said that it ended the year with more than $329.3 million in cash on its books, which doesn't include the proceeds from the voucher sale.Vetr Advises Hold On Sarepta - Benzinga"
p2
aS'Oppenheimer Stays Bullish on Sarepta Therapeutics Inc  as the Stock ... Smarter Analyst - Feb 16, 2017 Oppenheimer analyst Hartaj Singh is out with a new research note on shares of Sarepta Therapeutics Inc , reiterating an Outperform rating and price target of $76.Oppenheimer Holdings, Inc. Reiterates Outperform Rating for Sarepta ... - Chaffey BreezeOppenheimer On Sarepta Therapeutics, Inc.  - Smrt Stck Nws'
p3
aS'Option Market Alert: Sarepta Therapeutics Inc Implied Price Swing Hits An ... CML News - 17 hours ago No Risk Alert Here: Before we dive into any analysis we simply note that Sarepta Therapeutics Inc  risk is neither elevated nor depressed.'
p4
aS"Sarepta  Q4 Loss Widens; Sales of Duchenne Drug Slow Nasdaq - Mar 1, 2017 Sarepta Therapeutics, Inc. SRPT reported wider-than-expected loss in the fourth quarter of 2016. Meanwhile, the biotech company's 2017 sales outlook fell largely short of expectations as the commercial launch of its only approved drug, Exondys 51, has&nbsp;...Sarepta Therapeutics Inc  Stock Heads Higher on Analyst Upgrade - Investorplace.comSarepta Therapeutics, Inc. | $SRPT Stock | Shares Fall On Poor Fourth Quarter ... - TickerTV News "
p5
aS'Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M Yahoo Finance - Feb 21, 2017 Sarepta Therapeutics, Inc. , a commercial-stage developer of innovative RNA-targeted therapeutics, today announced it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher .Sarepta Therapeutics, Inc.  Files An 8-K Entry into a Material ... - Market ExclusiveCommit To Purchase Sarepta Therapeutics At $18, Earn 16.7% Using Options - Nasdaq'
p6
aS'Is a Surprise Coming for Sarepta Therapeutics  This Earnings Season? Yahoo Finance - Feb 27, 2017 Investors are always looking for stocks that are poised to beat at earnings season and Sarepta Therapeutics, Inc. SRPT may be one such company.'
p7
aS"Today's Research Reports on Biotech Stocks to Watch: Amicus Therapeutics and ... Yahoo Finance - Mar 17, 2017 The company's rating has recently raised by Vetr Inc. from &quot;buy&quot; to &quot;strong buy.&quot; Oppenheimer Holdings reiterated its &quot;outperform&quot; rating on February 28th. Number of &quot;buy&quot; recommendations currently outweighs the &quot;sell&quot; by a 11 to 1 ratio. Sarepta has ..."
p8
aS'Sarepta -2% after Q4 results Seeking Alpha - Feb 28, 2017 Q4 non-GAAP net loss of $38.7M or $0.71 per share vs. loss of $58.3M and $1.30 one year ago. Revenue of $5.4M recognized for EXONDYS 51 in Q4.'
p9
aS"Analysts Wary on Valeant Pharmaceuticals Intl Inc  as Salespeople Flee ... Smarter Analyst - Feb 24, 2017 Wells Fargo and Needham are chiming in with mixed takes on biotech companies Valeant Pharmaceuticals Intl Inc  and Sarepta Therapeutics Inc . One analyst is investigating rumblings that over 50 of Valeant's GI salespeople&nbsp;..."
p10
a.